Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameAnti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Antibody-armed T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-CD3Epidermal growth factor receptor erbB1 antagonists
TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBarbara Ann Karmanos Cancer InstituteUniversity Of Virginia
China Registration ClassN/A

Develop Information

Active CompaniesBarbara Ann Karmanos Cancer Institute
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A